Sensei Biotherapeutics Files 8-K on Shareholder Votes
Ticker: SNSE · Form: 8-K · Filed: May 23, 2025 · CIK: 1829802
| Field | Detail |
|---|---|
| Company | Sensei Biotherapeutics, Inc. (SNSE) |
| Form Type | 8-K |
| Filed Date | May 23, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, sec-filing
TL;DR
Sensei Biotherapeutics filed an 8-K for shareholder votes on May 21st.
AI Summary
Sensei Biotherapeutics, Inc. filed an 8-K on May 23, 2025, reporting on matters submitted to a vote of security holders as of May 21, 2025. The filing details the company's principal executive offices located at 1405 Research Blvd, Suite 125, Rockville, MD 20850, with a business phone number of (240) 243-8000. This report is filed under the Securities Exchange Act of 1934.
Why It Matters
This filing indicates that Sensei Biotherapeutics is engaging in corporate actions requiring shareholder approval, which could impact the company's strategic direction and governance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate actions and does not inherently present new financial or operational risks.
Key Players & Entities
- Sensei Biotherapeutics, Inc. (company) — Registrant
- May 21, 2025 (date) — Earliest event reported
- May 23, 2025 (date) — Filing date
- 1405 Research Blvd, Suite 125, Rockville, MD 20850 (location) — Principal Executive Offices
- (240) 243-8000 (phone_number) — Registrant's telephone number
FAQ
What specific matters were submitted to a vote of Sensei Biotherapeutics' security holders?
The filing states that the 8-K is for 'Submission of Matters to a Vote of Security Holders,' but the specific details of these matters are not provided in the excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on May 21, 2025.
What is the principal executive office address for Sensei Biotherapeutics, Inc.?
The principal executive offices are located at 1405 Research Blvd, Suite 125, Rockville, MD 20850.
Under which section of the Securities Exchange Act is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 23, 2025 regarding Sensei Biotherapeutics, Inc. (SNSE).